CA Patent

CA2890981C — Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses

Assigned to Bristol Myers Squibb Co · Expires 2022-07-05 · 4y expired

What this patent protects

Amide-substituted heterocyclic compounds having the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition. Such compounds include …

USPTO Abstract

Amide-substituted heterocyclic compounds having the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition. Such compounds include in particular the compound having the structure: useful in treating systemic lupus erythematosus, psoriasis, psoriatic arthritis, lupus nephritis, Sjögren's syndrome, inflammatory bowel disease, Crohn's disease, ankylosing spondylitis

Drugs covered by this patent

Patent Metadata

Patent number
CA2890981C
Jurisdiction
CA
Classification
—
Expires
2022-07-05
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.